In that respect, Cabozantinib inhibits tyrosine kinases, including the VEGF receptors 1, 2, and 3, MET, and AXL, which are involved in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, which is the conventional first-line treatment for advanced HCC [37]. Here, AXL is linked to hepatocellular carcinoma.